Scarica l'app Stockscreener
7.07
3.68%
-0.27
Dopo l'orario di chiusura:
7.09
0.02
+0.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVAX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.34
Aprire:
$7.33
Volume 24 ore:
6.97M
Relative Volume:
0.85
Capitalizzazione di mercato:
$1.15B
Reddito:
$847.25M
Utile/perdita netta:
$-284.86M
Rapporto P/E:
-3.0873
EPS:
-2.29
Flusso di cassa netto:
$-112.35M
1 W Prestazione:
-2.48%
1M Prestazione:
+10.30%
6M Prestazione:
-19.38%
1 anno Prestazione:
-52.96%
Intervallo 1D:
$6.92
$7.34
Intervallo di 1 settimana:
$6.84
$7.62
Portata 52W:
$5.01
$23.86
Novavax Inc Stock (NVAX) Company Profile
Nome
Novavax Inc
Settore
Industria
Telefono
240-268-2000
Indirizzo
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Confronta NVAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
7.07 | 1.20B | 847.25M | -284.86M | -112.35M | -2.29 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-28 | Iniziato | BTIG Research | Buy |
| 2024-07-30 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Reiterato | B. Riley Securities | Buy |
| 2022-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-02 | Iniziato | Jefferies | Hold |
| 2022-09-22 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Iniziato | BofA Securities | Underperform |
| 2022-02-23 | Reiterato | B. Riley Securities | Buy |
| 2022-02-22 | Ripresa | Jefferies | Buy |
| 2022-01-21 | Iniziato | Cowen | Outperform |
| 2021-05-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Reiterato | B. Riley FBR | Buy |
| 2020-06-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Reiterato | B. Riley FBR | Buy |
| 2020-05-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-27 | Ripresa | B. Riley FBR | Buy |
| 2019-08-14 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-28 | Downgrade | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-11 | Iniziato | Oppenheimer | Outperform |
| 2018-11-26 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Aggiornamento | Seaport Global Securities | Neutral → Buy |
Mostra tutto
Novavax Inc Borsa (NVAX) Ultime notizie
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals - Benzinga
Novavax (NVAX) Sees Surge in Bullish Option Activity | NVAX Stoc - GuruFocus
US CDC continues to recommend COVID vaccines for children, contradicts Kennedy - marketscreener.com
Novavax (NVAX) Sees Surge in Bullish Option Activity | NVAX Stock News - GuruFocus
RFK Jr. Drops COVID Vaccine Recommendation For Healthy Kids, But Experts Warn Of Major Risks - Benzinga
Novavax to Participate in Upcoming Investor Conferences - Quantisnow
Novavax to Participate in Upcoming Investor Conferences | NVAX S - GuruFocus
Novavax Announces June Presentations at Jefferies and Goldman Sachs Conferences | NVAX Stock News - Stock Titan
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novavax eliminates COO role, parts ways with longtime exec amid business model shift - The Business Journals
(NVAX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Novavax Eliminates COO Position, Trizzino to Consult - TipRanks
Novavax IncEliminates COO Position, Terminates John TrizzinoSEC Filing - marketscreener.com
Here's Why Novavax (NVAX) is a Strong Momentum Stock - Yahoo Finance
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax COVID-19 vaccine approved by the FDA - MSN
Gaithersburg-Based Novavax Receives FDA Approval for COVID-19 Vaccine for High-Risk Groups - The MoCo Show -
JPMorgan Maintains Underweight Rating on Novavax (NVAX) Stock Despite Positive News - MSN
Novavax Target of Unusually High Options Trading (NASDAQ:NVAX) - Defense World
BofA Reiterates Hold Rating on Novavax (NVAX) Stock - MSN
Analysts Think These Stocks Could More Than Double in Value - MarketBeat
Rx Rundown: BioMarin, Novavax, CellCentric and more - Medical Marketing and Media
Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of “Hold” by Analysts - Defense World
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine - MSN
NVAX July 3rd Options Begin Trading - Nasdaq
New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say - insights.citeline.com
Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli (NASDAQ:NVAX) - Seeking Alpha
Novavax Soars After Covid Vaccine Secures Full FDA Approval - MSN
Novavax Stock (NVAX) Shoots 15% Higher as Covid Vaccine Jab Gets FDA Green Light - The Globe and Mail
US FDA advisers to consider if new COVID shots should target LP.8.1 subvariant - marketscreener.com
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 29% But Investors Aren't Buying For Growth - simplywall.st
Novavax’s COVID-19 Vaccine Label Narrowed After Political Officials Intervened - insights.citeline.com
Dow Surges Over 100 Points Despite Moody's US Downgrade: Fear Index Remains In 'Greed' Zone - Benzinga
US Markets Show Mixed Signals Amid Rating Downgrades And Rising Earnings - Finimize
Novavax Receives FDA Approval for Nuvaxovid Vaccine for High-Risk Populations - madisongraph.com
Novavax gets FDA nod for Nuvaxovid vaccine in high-risk groups By Investing.com - Investing.com South Africa
JPMorgan maintains Novavax stock Underweight with $7 target By Investing.com - Investing.com Nigeria
FDA Clears Novavax, Inc. (NVAX)’s COVID-19 Vaccine with Usage Restrictions - MSN
Third COVID Vaccine Gets Approved for Adults 65 and Over - AARP
These Stocks Moved the Most Today: Nvidia, Tesla, UnitedHealth, JPMorgan, SMCI, Palantir, Novavax, and More - Barron's
With FDA vaccine nod, Novavax takes ACIP of new COVID-19 rules - BioWorld MedTech
FDA Approval Boosts Novavax (NVAX) with $200M Milestone | NVAX S - GuruFocus
Novavax, Shake Shack, solar stocks: Trending Tickers - Yahoo Finance
Novavax gets FDA nod for Nuvaxovid vaccine in high-risk groups - Investing.com Australia
Novavax Shares Jump 17% FDA Grants Full Approval to COVID Vaccine - Yahoo Finance
Stocks Mixed, Treasury Bonds Slip On Moody's US Downgrade: What's Driving Markets Monday? - Benzinga
US Approves Novavax Covid Jab After Delay, Adds Restrictions - Barron's
Novavax secures FDA approval for COVID-19 vaccine - Investing.com Australia
Novavax secures FDA approval for COVID-19 vaccine By Investing.com - Investing.com Nigeria
FDA approves Novavax COVID vaccine with new conditions - Reuters
Novavax’s COVID vaccine gets FDA approval, but with limits - BioPharma Dive
Novavax Inc Azioni (NVAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):